Literature DB >> 17127777

Randomized controlled trial of ipratropium bromide and salbutamol versus salbutamol alone in children with acute exacerbation of asthma.

Amitabha Chakraborti1, Rakesh Lodha, R M Pandey, S K Kabra.   

Abstract

OBJECTIVE: To evaluate effect of addition of ipratropium to salbutamol delivered by metered dose inhaler and spacer in the beginning of treatment of mild to moderate exacerbation of asthma.
METHODS: Children between 5 to 15 years of age with mild to moderate exacerbation of asthma were randomized to receive either a combination of ipratropium bromide and salbutamol or salbutamol alone administered by metered dose inhaler and spacer. The effects on clinical asthma score and spirometric parameters were compared.
RESULTS: A total of 60 children were randomized in the study. The baseline characteristics of two groups were comparable. Children getting combination of salbutamol and ipratropium showed significantly greater improvement in percent-predicted PEFR and FEF25-75% than children receiving salbutamol alone.
CONCLUSION: There was beneficial effect of addition of ipratropium to salbutamol administered by MDI with spacer at the beginning of therapy for mild to moderate acute exacerbation of asthma in children.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17127777     DOI: 10.1007/bf02758300

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  19 in total

Review 1.  Mechanisms of virus induced exacerbations of asthma.

Authors:  J M Corne; S T Holgate
Journal:  Thorax       Date:  1997-04       Impact factor: 9.139

2.  Efficacy of nebulized ipratropium in severely asthmatic children.

Authors:  F Qureshi; A Zaritsky; H Lakkis
Journal:  Ann Emerg Med       Date:  1997-02       Impact factor: 5.721

3.  First-line therapy for adult patients with acute asthma receiving a multiple-dose protocol of ipratropium bromide plus albuterol in the emergency department.

Authors:  G J Rodrigo; C Rodrigo
Journal:  Am J Respir Crit Care Med       Date:  2000-06       Impact factor: 21.405

4.  Nebulised ipratropium and salbutamol in asthma.

Authors:  J Storr; W Lenney
Journal:  Arch Dis Child       Date:  1986-06       Impact factor: 3.791

5.  Randomized trial of the addition of ipratropium bromide to albuterol and corticosteroid therapy in children hospitalized because of an acute asthma exacerbation.

Authors:  N Goggin; C Macarthur; P C Parkin
Journal:  Arch Pediatr Adolesc Med       Date:  2001-12

6.  Factors associated with severe asthma.

Authors:  V H Ratageri; S K Kabra; S N Dwivedi; V Seth
Journal:  Indian Pediatr       Date:  2000-10       Impact factor: 1.411

7.  Efficacy of IV theophylline in children with severe status asthmaticus.

Authors:  R S Ream; L L Loftis; G M Albers; B A Becker; R E Lynch; R B Mink
Journal:  Chest       Date:  2001-05       Impact factor: 9.410

8.  Efficacy of frequent nebulized ipratropium bromide added to frequent high-dose albuterol therapy in severe childhood asthma.

Authors:  S Schuh; D W Johnson; S Callahan; G Canny; H Levison
Journal:  J Pediatr       Date:  1995-04       Impact factor: 4.406

Review 9.  Holding chambers versus nebulisers for beta-agonist treatment of acute asthma.

Authors:  C J Cates; B H Rowe; A Bara
Journal:  Cochrane Database Syst Rev       Date:  2002

10.  Effect of nebulized ipratropium on the hospitalization rates of children with asthma.

Authors:  F Qureshi; J Pestian; P Davis; A Zaritsky
Journal:  N Engl J Med       Date:  1998-10-08       Impact factor: 91.245

View more
  2 in total

1.  Achieving control of asthma in preschoolers.

Authors:  Thomas Kovesi; Suzanne Schuh; Sheldon Spier; Denis Bérubé; Stuart Carr; Wade Watson; R Andrew McIvor
Journal:  CMAJ       Date:  2009-11-23       Impact factor: 8.262

2.  Combination of ipratropium bromide and salbutamol in children and adolescents with asthma: A meta-analysis.

Authors:  Hongzhen Xu; Lin Tong; Peng Gao; Yan Hu; Huijuan Wang; Zhimin Chen; Luo Fang
Journal:  PLoS One       Date:  2021-02-23       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.